Latest news
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 16:51:52 GMTFDA Clears Trodelvy as First-Line Therapy for TNBC - Clinical Oncology NewsClinical Oncology News · Thu, 06 Aug 2026 19:42:10 GMTNeoadjuvant Sacituzumab Govitecan in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Brigida Maiorano - UroTodayUroToday · Thu, 06 Aug 2026 00:32:57 GMTOptimizing Neutropenia Management With Sacituzumab Govitecan - OncLiveOncLive · Tue, 04 Aug 2026 14:24:42 GMTFDA Approves Two New Treatments For Metastatic TNBC - Breast Cancer.orgBreast Cancer.org · Wed, 29 Jul 2026 12:32:32 GMT